Company Insights

VEEV customer relationships

Explore interactive graphBrowse insights index

VEEV customers relationship map

Veeva’s customer map: how enterprise life‑sciences relationships underwrite recurring growth

Veeva runs a subscription‑first, enterprise cloud business that sells software, data, and professional services into the life‑sciences value chain; the company monetizes through recurring subscription agreements, add‑on data products, and consulting engagements that drive high retention and multi‑year expansion. For investors, the signal is straightforward: revenue predictability and expansion depend on large strategic wins with global pharma and deep adoption across clinical, regulatory, and commercial functions. Learn more at https://nullexposure.com/.

The business model in one paragraph: subscriptions, expansion, and strategic embeds

Veeva sells cloud software and related services under master subscription agreements with annual order cycles, which creates a steady revenue base and predictable renewal cadence. The product suite spans Vault (clinical/regulatory), Vault CRM (commercial), Data Cloud, AI agents, and QMS; strategic partnerships and enterprise rollouts convert point deployments into platformwide adoption and incremental professional services revenue. Top‑10 customer concentration (≈28% of revenue) coexists with a broad installed base, so growth is driven by both large enterprise conversions (CRM, AI) and cross‑sell into small and mid‑sized biotechs.

Operating constraints and what they imply for investors

  • Contracting posture — subscription and one‑year order terms. Veeva counts customers at the master subscription level and recognizes that most subscription orders carry one‑year terms, which supports visibility but keeps renewal cycles frequent.
  • Customer mix — broad but not undifferentiated. The company serves both global pharma and smaller, pre‑commercial companies; Veeva’s software is widely used by smaller R&D organizations even if they are less commercially material.
  • Geography — global footprint with North America dominance. As of FY2025 subscription mix is 59% North America, 28% Europe, 13% other (primarily APAC), indicating revenue exposure concentrated in developed markets while retaining growth opportunity abroad.
  • Concentration — measurable but manageable. No single customer exceeds 10% of total revenue, yet the top 10 customers accounted for ~28% of revenue in FY2025, signaling reliance on a cohort of large enterprises for outsized growth.
  • Role and delivery — direct sales plus services. Veeva sells through its direct sales organization and supplements product revenue with professional services and consulting, which increases stickiness but also raises the cost to onboard large customers.
  • Customer lifecycle — mature, active base. The installed base exceeded 1,400 customers by Jan 31, 2025, showing a mature set of recurring relationships available for expansion via new modules and AI capabilities.
    Together these constraints paint a platform vendor with predictable subscription economics, geographic concentration in developed markets, and growth driven by enterprise rollouts and cross‑sell.

Customer relationships: the on‑record roll call

Below are Veeva’s customer relationships pulled from public releases and trade coverage; each entry has a short plain‑English summary and a concise source reference.

  • Walgreens / WBA — Veeva and Walgreens formed a strategic partnership to integrate Walgreens into Veeva Data Cloud and the Veeva Clinical Platform so Walgreens can better serve life‑sciences customers. Source: Veeva press release on the Walgreens strategic partnership (FY2024) published on veeva.com, first seen Mar 10, 2026.

  • AOP Health — AOP Health standardized across the Veeva Vault platform to run rare‑disease and critical‑care operations, representing a full‑platform adoption across clinical, regulatory, safety, and commercial workflows. Source: Veeva announcement reported by Sahm Capital and PR Newswire (Mar 10, 2026).

  • Gilead Sciences / GILD — Gilead committed to Veeva Vault CRM as part of broader enterprise CRM adoption, including embedded AI agents designed to improve commercial execution. Source: Sahm Capital write‑up on Vault CRM commitments (Sept 23, 2025).

  • Merck / MRK — Merck announced a commitment to Veeva’s Vault CRM in a move that reflects adoption of Veeva’s next‑gen commercial platform. Source: Sahm Capital analysis noting Merck’s August 2025 Vault CRM commitment (FY2025).

  • Bristol Myers Squibb / BMY — Bristol‑Myers committed to Vault CRM, joining other large pharmas in adopting Veeva’s AI‑enabled commercial platform. Source: Sahm Capital coverage (Sept 23, 2025).

  • BioMarin / BMRN — BioMarin expanded a long‑term enterprise agreement with Veeva to increase speed and operational efficiency by leveraging Veeva software, data, services, and consulting. Source: Veeva and PR Newswire announcement (Jan 8, 2026).

  • Crinetics / CRNX — Crinetics stated it will use Veeva’s AI Free Text Agent as part of its AI strategy, indicating early adoption among small‑to‑mid biotechs for AI‑enabled workflows. Source: Sahm Capital summary of Veeva AI Agents availability (Dec 3, 2025).

  • Moderna / MRNA — Moderna participated as an early access user of Veeva’s AI Quick Check Agent, reporting that the tool moves MLR (medical/legal/regulatory) processes toward nearly touch‑free checks. Source: Sahm Capital report on Veeva AI agents (Dec 3, 2025).

  • IQVIA / IQV — IQVIA joined Veeva’s CRO Clinical Data Partner program and gained the ability to execute trials using Veeva Clinical Suite products, including EDC study builds. Source: MedTech Intelligence coverage of the IQVIA partnership (FY2025).

  • Bayer AG / BAYRY — Bayer integrated Veeva’s Link Key People data into its platforms, using the data to enrich AI‑driven outputs and business insights across customer engagement. Source: Sahm Capital article on Link Key People adoption (Feb 4, 2026).

  • Novo Nordisk / NVO — Novo Nordisk’s International Operations committed to Veeva Vault CRM, expanding Veeva’s footprint in global commercial teams. Source: Veeva announcement covered by Sahm Capital and RTTNews (Jan 7, 2026).

  • Roche / RHHBY (Roche Pharmaceuticals) — Roche expanded a global rollout of Vault CRM with advanced AI capabilities across its pharmaceutical operations. Source: Sahm Capital analysis and follow‑up StockTITAN coverage noting partnership expansion (Nov 30, 2025; FY2025–FY2026).

  • BioDlink — BioDlink went live with Veeva QMS, adopting a cloud quality‑management platform to support regulated processes. Source: Sahm Capital piece on Veeva QMS and BioDlink go‑live (Feb 12, 2026).

  • SK Life Science, Inc. — SK Life Science adopted Veeva Vault Validation Management to streamline validation processes and accelerate digital validation execution. Source: Veeva resource announcement on veeva.com (FY2024).

  • Otsuka Europe — Otsuka Europe highlighted the importance of embedding Veeva AI into existing Veeva applications as it expanded its partnership and shared innovation with leadership. Source: Sahm Capital report on AI agents availability (Dec 3, 2025).

(These entries reflect Veeva press releases and trade coverage that demonstrate both large strategic rollouts and targeted adoption by smaller biotechs.)

What investors should watch next

  • Expansion vs. headline deals: Large CRM rollouts (Roche, Novo Nordisk, Gilead, Merck, BMS) are the primary growth drivers because they create global seat/license expansion and data monetization opportunities; monitor implementation timelines and professional services revenue as leading indicators.
  • AI adoption as a multiplier: Early AI pilots (Moderna, Crinetics, Otsuka) validate product differentiation; quick conversion from pilot to enterprise‑wide AI agents will materially accelerate ACV expansion.
  • Concentration risk balanced by scale: The top‑10 concentration (~28%) increases investor reliance on a handful of enterprise renewals, but the company’s >1,400 customers provide diversification and cross‑sell runway.
  • Geographic exposure: With ~59% of subscription revenue in North America, execution outside the U.S. (EMEA/APAC) is critical to sustain multi‑year growth.

Bold conclusion: Veeva’s customer roster shows clear enterprise validation of its platform strategy—global pharma CRM rollouts and strategic partnerships for data and AI are the primary engines of durable, recurring revenue. For a concise briefing on how these customer dynamics affect valuation and risk, visit https://nullexposure.com/.

Join our Discord